No connection

Search Results

BMGL vs GDTC

BMGL
Basel Medical Group Ltd
BEARISH
Price
$0.80
Market Cap
$15.0M
Sector
Healthcare
AI Confidence
85%
GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BMGL
--
GDTC
--
Forward P/E
BMGL
--
GDTC
-6.67
P/B Ratio
BMGL
3.96
GDTC
2.31
P/S Ratio
BMGL
1.24
GDTC
13.74
EV/EBITDA
BMGL
-9.1
GDTC
-2.73

Profitability

Gross Margin
BMGL
26.29%
GDTC
89.57%
Operating Margin
BMGL
-9.47%
GDTC
-535.25%
Profit Margin
BMGL
-99.84%
GDTC
0.0%
ROE
BMGL
-194.56%
GDTC
-50.28%
ROA
BMGL
-4.67%
GDTC
-29.31%

Growth

Revenue Growth
BMGL
32.2%
GDTC
46.9%
Earnings Growth
BMGL
--
GDTC
--

Financial Health

Debt/Equity
BMGL
1.04
GDTC
0.07
Current Ratio
BMGL
1.23
GDTC
5.17
Quick Ratio
BMGL
1.15
GDTC
3.14

Dividends

Dividend Yield
BMGL
--
GDTC
--
Payout Ratio
BMGL
0.0%
GDTC
0.0%

AI Verdict

BMGL BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and profitability concerns. Despite a positive revenue growth of 32.20% YoY and a gross margin of 26.29%, the company suffers from catastrophic profitability metrics including a -99.84% profit margin and -194.56% ROE, which undermine sustainable growth. Valuation multiples like Price/Book of 3.96 appear high given the lack of earnings and cash flow visibility, while the stock has lost over 80% of its value in the past year. The absence of Altman Z-Score and intrinsic value estimates further reflects data insufficiency and elevated distress risk.

Strengths
Revenue growth of 32.20% YoY indicates some top-line momentum
Gross margin of 26.29% suggests basic operational viability in core services
Current ratio of 1.23 and quick ratio of 1.15 indicate short-term liquidity adequacy
Risks
Piotroski F-Score of 2/9 signals extreme financial weakness and high risk of deterioration
Profit margin of -99.84% and ROE of -194.56% indicate severe unprofitability and capital destruction
No Altman Z-Score available, but negative earnings and ROE imply potential distress risk (Z < 1.8 likely)
GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage

Compare Another Pair

BMGL vs GDTC: Head-to-Head Comparison

This page compares Basel Medical Group Ltd (BMGL) and CytoMed Therapeutics Limited (GDTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile